These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24953762)

  • 1. Effects of change in the formulation of lanthanum carbonate on laboratory parameters.
    Takita T; Furuhashi M; Fujimoto T; Suzuki H; Harada M; Maruyama S; Tamiya R; Kamiya E; Okamoto M; Tukada A; Furuhashi M; Kato A
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():18-22. PubMed ID: 24953762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
    Mukai I; Yoshizawa T; Kumagai J; Takahashi N; Tsuchiya S
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():28-33. PubMed ID: 24953764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is granular formulation of lanthanum carbonate more effective than chewable tablets?
    Okamoto H; Haruhara K; Kamejima S; Mafune H; Manabe M; Kanzaki G; Mashiko H; Yokoo T
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():23-7. PubMed ID: 24953763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
    Sakurada T; Oishi D; Shibagaki Y; Yasuda T; Kimura K
    Hemodial Int; 2013 Oct; 17 Suppl 1():S2-6. PubMed ID: 24134326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
    Yamashita T; Ogawa T; Takahashi M; Mitsuhashi T; Shizuku J; Takahashi N; Ohba T; Miyajima S; Kabaya T; Otsuka K; Nitta K
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():54-9. PubMed ID: 23586514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
    Manabe R; Fukami K; Ando R; Sakai K; Kusumoto T; Hazama T; Adachi T; Kaida Y; Nakayama Y; Ueda S; Kohno K; Wada Y; Yamagishi S; Okuda S
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():35-40. PubMed ID: 23586511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
    Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
    Pierce D; Hossack S; Robinson A; Zhang P; Martin P
    Clin Ther; 2012 Jun; 34(6):1290-1300.e2. PubMed ID: 22657252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.
    Hyodo T; Kawakami J; Mikami N; Wakai H; Ishii D; Yoshida K; Iwamura M; Hida M; Kurata Y
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():14-7. PubMed ID: 24953761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
    Wei Y; Kong XL; Li WB; Wang ZS
    Ther Apher Dial; 2014 Dec; 18(6):618-22. PubMed ID: 24674384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
    Vemuri N; Michelis MF; Matalon A
    BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
    Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
    How PP; Anattiwong P; Mason DL; Arruda JA; Lau AH
    Hemodial Int; 2011 Jan; 15(1):95-9. PubMed ID: 21138519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].
    Arenas MD; Malek T; Álvarez-Ude F; Gil MT; Moledous A; Reig-Ferrer A
    Nefrologia; 2010; 30(5):522-30. PubMed ID: 20613851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients.
    Wang XH; Zhang X; Mu CJ; He Y; Peng QP; Yang GS; Li MM; Liu D; Li J; Ding GH
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):508-513. PubMed ID: 26223918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
    Ota S; Hirose M; Izumiya Y; Ishida Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():49-53. PubMed ID: 23586513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.